3 completed. 3 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Acticor Biotech: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo Intravenous glenzocimab (ACT017) 1000 mg, Intravenous Placebo - Acute Ischemic Stroke | Phase 2 / Phase 3 | Completed | Acticor Biotech | 438 | 2021-09-23 | 2024-07-03 |
| Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19 glenzocimab, Placebo - SARS-CoV Infection, Acute Respiratory Distress Syndrome | Phase 2 | Completed | Acticor Biotech | 60 | 2020-12-16 | 2021-09-13 |
| Acute Ischemic Stroke Interventional Study Intravenous ACT017 1000 mg, Intravenous Placebo - Acute Ischemic Stroke | Phase 1 / Phase 2 | Completed | Acticor Biotech | 160 | 2019-03-06 | 2021-10-06 |
Ischemic Stroke (2) · Stroke (2) · COVID-19 (1) · Hemorrhage (1) · Respiratory Distress Syndrome (1) · Severe Acute Respiratory Syndrome (1)
glenzocimab (2)
France (2) · Germany (1) · United States (1)
PMID 42044230, PMID 38267188, PMID 38885234
2018 (1)